Effective June 22, 2022, Medicaid and NC Health Choice cover Nalmefene hydrochloride injection (Revex™)
Topics Related to Bulletins
Effective June 22, 2022, Medicaid and NC Health Choice cover Risankizumab-rzaa Injection, for intravenous use (Skyrizi).
Effective June 21, 2022, Medicaid and NC Health Choice cover Vutrisiran injection, for subcutaneous use (Amvuttra).
The PDAP Medicaid fee schedule requires multiple rate updates
Evaluates the impact of the North Carolina Medicaid Transformation on primary care and obstetrics/gynecology (Ob/Gyn) practices
CAHPS is a patient experience survey that serves as a national standard for measuring and reporting respondents’ experiences with their health care.
Quality metrics that will assess health plans’ performance across their populations
An amended version is posted with an effective date of Aug. 1, 2022
A delay in identifying individuals in NCTracks as dually eligible for Medicare and Medicaid has been discovered.
Proposed CAP/C Waiver renewal posted for public comment